Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$15.43 USD
+0.47 (3.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNLI 15.43 +0.47(3.14%)
Will DNLI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
Other News for DNLI
First Week of DNLI December 20th Options Trading
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Denali Therapeutics price target lowered by $38 at UBS, here's why
Denali Therapeutics files to sell 29.29M shares of common stock for holders